KLRS logo

KLRS
Kalaris Therapeutics

121
Mkt Cap
$111.76M
Volume
88,982.00
52W High
$11.88
52W Low
$2.14
PE Ratio
-2.30
KLRS Fundamentals
Price
$4.92
Prev Close
$5.12
Open
$5.08
50D MA
$5.93
Beta
0.83
Avg. Volume
91,903.74
EPS (Annual)
-$2.85
P/B
1.65
Rev/Employee
$0.00
$12.33
Loading...
Loading...
News
all
press releases
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant decrease in short interest in April. As of April 15th, there was short interest totaling 842,687 shares, a decrease of...
News Placeholder
More News
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has earned an average rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. One investment...
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) CAO Sells 1,915 Shares
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of Kalaris Therapeutics stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $6.72, for a total transaction of $12,868.80. The transaction was disclosed in a legal...
News Placeholder
Brett Hagen Sells 1,915 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of the firm's stock in a transaction dated Friday, March 20th. The shares were sold at an average price of...
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday...
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the company, Marketbeat.com...
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered shares of Kalaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
News Placeholder
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold
Wall Street Zen raised Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
News Placeholder
Srinivas Akkaraju Buys 479,847 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju purchased 479,847 shares of Kalaris Therapeutics stock in a transaction dated Thursday, December 18th. The stock...
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju acquired 479,847 shares of the stock in a transaction dated Thursday, December 18th. The shares were purchased at...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available